$140 MILLION VERDICT AGAINST ABBVIE IN ANDROGEL BELLWETHER TRIAL!

A second consecutive plaintiff’s verdict was reached by a federal jury in Illinois in the Prescription Testosterone Products Liability Litigation.  The jury awarded $140,000 in compensatory damages to Plaintiff Jeffrey Konrad for the heart attack he suffered while using AndroGel, as well as $140 million in punitive damages related to the manufacturer, AbbVie, falsely and aggressively marketing the drug for use to combat age-related low testosterone.

This is the second bellwether trial victory for plaintiffs in the United States District Court for the District of Northern Illinois, the home of the Prescription Testosterone Products Liability Litigation MDL being presided over by Judge Matthew F. Kennelly.  The first trial, for plaintiff Jesse Mitchell, resulted in a $150 million award for punitive damages based on AbbVie’s fraudulent misrepresentation of AndroGel in their marketing.

Numerous studies have linked testosterone therapy with increased risks for heart attacks, strokes, blood clots, and even death.  Older men have been shown to be even more susceptible to these risk increases.  In addition to these increased health risks, testimony in both bellwether trials has convinced juries that AbbVie formulated a marketing strategy to aggressively advertise their product directly to men by falsely linking it as a cure for “Low T,” representing men’s problems with weight gain, muscle loss, lack of energy, and especially libido problems.

If you or a loved one has experienced a cardiac event such as a heart attack or stroke or a blood clot such as a DVT or PE after using a Low T medication, you may be entitled to compensation. Contact the Low-T lawyers at the Levensten Law Firm at www.levenstenlawfirm.comwww.androgellawyers.com or 215-545-5600 for a free consultation.